ABSTRACT
Objective To evaluate the cost-effectiveness of a personalised medicine strategy for Crohn’s disease in the UK, using early targeted top-down therapy compared to standard of care.
Materials & Methods A decision tree leading into a Markov state-transition model was constructed, allowing comparison of two treatment approaches: 1) standard of care therapy following established UK clinical guidelines (‘step-up’ treatment) and 2) a personalised medicine strategy in which patients identified as high-risk of subsequent relapse using a prognostic biomarker receive ‘top-down’ anti-TNF treatment at diagnosis. The model facilitated comparison of both costs and Quality Adjusted Life Years (QALYs) in a hypothetical cohort of newly diagnosed Crohn’s disease patients with sensitivity analyses undertaken to model the impact of key assumptions.
Results Early personalised treatment with anti-TNF based combination therapy resulted in an incremental cost-effectiveness ratio (ICER) of £2,176 per quality-adjusted life year (QALY), with £717 incremental costs and 0.330 incremental QALYs, substantially below the NICE cost-effectiveness threshold of between £20,000 and £30,000 per QALY. Additional costs relating to earlier biologic use were offset by incremental QALYS and reductions in costs driven by fewer disease flares and hospitalisations. Sensitivity analysis across a wide range of parameter assumptions did not impact on the model’s conclusion.
Conclusion A personalised medicine strategy using anti-TNF therapy at diagnosis in Crohn’s disease to patients at high risk of subsequent relapse is highly likely to be a cost-effective use of resources in the UK National Health Service.
Established Knowledge
Currently there are no validated prognostic test that can stratify IBD patients based on long term outcomes at the point of diagnosis used routinely in the UK
It therefore remains unclear which patients with Crohn’s disease should be treated with early anti-TNF based therapy as part of a ‘top-down’ regimen.
As a consequence, the majority of IBD patients in the UK are currently treated with an accelerated step-up approach
Significant new findings
We show here that the use of biomarkers at diagnosis to guide personalised use of such treatment is a cost-effective approach for treatment of Crohn’s disease.
Use of a prognostic test to deliver personalised medicine for Crohn’s disease results in positive QALY of 0.330
The approach is cost effective with an incremental cost of £717 and an ICER of 2,176
The model’s conclusions were unaffected by a wide range of sensitivity analyses
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of Interest: VB, SG and WT of Cogentia Healthcare Consulting were contracted to build the economic model by PredictImmune (PI) Ltd who funded the work. KGCS, PAL, JCL and EFM received consultancy fees from PI and KGCS, PAL and EFM are academic co-founders of and hold equity in PredictImmune Ltd.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
